Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1988 Jan;57(1):121–126. doi: 10.1038/bjc.1988.24

Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma.

H Christiansen 1, F Lampert 1
PMCID: PMC2246687  PMID: 3348945

Abstract

In 28 patients with neuroblastoma of different stages the karyotype was determined in the primary tumour and/or in the metastases by direct chromosome preparation or short term cell culture. In addition, DNA analysis for the proto-oncogene N-myc was performed for comparison in 10 cases. Abnormalities (deletions, translocations, derivations) of the short arm of chromosome 1 with the most frequent breakpoint at 1p32 (besides rarer aberrations in other chromosomes) were found in the tumour karyotype of 15 of 18 (83%) patients with metastatic disease (stage IV) and in 2 of 3 patients with stage III, but in none of the 7 patients with stages I, II, IV-S who are all alive with no evidence of disease. These 7 surviving patients with good prognosis had a hyperploid tumour karyotype, mainly in the triploid range. Eleven of the 18 (61%) patients with stage IV and 1 of 3 patients with stage III also contained double minutes (DMs) and/or homogeneously staining regions (HSRs) in their tumour karyotypes. N-myc amplification (30 to 60 copies) in the tumour DNA was detected in 2 of 6 (33%) examined cases with stage IV, in 1 out of 2 examined cases with stage III, and correlated with the presence of DMs/HSRs. Life table analysis showed a 90% probability of surviving in patients lacking the 1p abnormality as compared to less than 10% in patients with an aberrant 1p chromosome in the tumour cells. We conclude that tumour karyotype, in particular the structure of the short arm of chromosome 1, is the most important factor in determining the different outcome in children with neuroblastoma.

Full text

PDF
121

Images in this article

124Figure 1
on p.124
124Figure 2
on p.124

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brodeur G. M., Green A. A., Hayes F. A., Williams K. J., Williams D. L., Tsiatis A. A. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res. 1981 Nov;41(11 Pt 1):4678–4686. [PubMed] [Google Scholar]
  2. Brodeur G. M., Seeger R. C., Schwab M., Varmus H. E., Bishop J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984 Jun 8;224(4653):1121–1124. doi: 10.1126/science.6719137. [DOI] [PubMed] [Google Scholar]
  3. Christiansen H., Franke F., Bartram C. R., Adolph S., Rudolph B., Harbott J., Reiter A., Lampert F. Evolution of tumor cytogenetic aberrations and N-myc oncogene amplification in a case of disseminated neuroblastoma. Cancer Genet Cytogenet. 1987 Jun;26(2):235–244. doi: 10.1016/0165-4608(87)90057-4. [DOI] [PubMed] [Google Scholar]
  4. Evans A. E., D'Angio G. J., Propert K., Anderson J., Hann H. W. Prognostic factor in neuroblastoma. Cancer. 1987 Jun 1;59(11):1853–1859. doi: 10.1002/1097-0142(19870601)59:11<1853::aid-cncr2820591102>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  5. Franke F., Förster W., Rudolph B., Lampert F. Metastatic neuroblastoma in an infant: translocation (1;11), deletion (2) and double minute chromosomes. Eur J Pediatr. 1985 Mar;143(4):305–308. doi: 10.1007/BF00442308. [DOI] [PubMed] [Google Scholar]
  6. Franke F., Rudolph B., Christiansen H., Harbott J., Lampert F. Tumour karyotype may be important in the prognosis of human neuroblastoma. J Cancer Res Clin Oncol. 1986;111(3):266–272. doi: 10.1007/BF00389243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Franke F., Rudolph B., Lampert F. Translocation (19;?) in two stage II neuroblastomas. Cancer Genet Cytogenet. 1986 Feb 1;20(1-2):129–135. doi: 10.1016/0165-4608(86)90116-0. [DOI] [PubMed] [Google Scholar]
  8. Gansler T., Chatten J., Varello M., Bunin G. R., Atkinson B. Flow cytometric DNA analysis of neuroblastoma. Correlation with histology and clinical outcome. Cancer. 1986 Dec 1;58(11):2453–2458. doi: 10.1002/1097-0142(19861201)58:11<2453::aid-cncr2820581117>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  9. Gilbert F., Feder M., Balaban G., Brangman D., Lurie D. K., Podolsky R., Rinaldt V., Vinikoor N., Weisband J. Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res. 1984 Nov;44(11):5444–5449. [PubMed] [Google Scholar]
  10. Hayashi Y., Habu Y., Fujii Y., Hanada R., Yamamoto K. Chromosome abnormalities in neuroblastomas found by VMA mass screening. Cancer Genet Cytogenet. 1986 Aug;22(4):363–364. doi: 10.1016/0165-4608(86)90029-4. [DOI] [PubMed] [Google Scholar]
  11. Look A. T., Hayes F. A., Nitschke R., McWilliams N. B., Green A. A. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984 Jul 26;311(4):231–235. doi: 10.1056/NEJM198407263110405. [DOI] [PubMed] [Google Scholar]
  12. Rosen N., Reynolds C. P., Thiele C. J., Biedler J. L., Israel M. A. Increased N-myc expression following progressive growth of human neuroblastoma. Cancer Res. 1986 Aug;46(8):4139–4142. [PubMed] [Google Scholar]
  13. Schwab M., Alitalo K., Klempnauer K. H., Varmus H. E., Bishop J. M., Gilbert F., Brodeur G., Goldstein M., Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature. 1983 Sep 15;305(5931):245–248. doi: 10.1038/305245a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES